Page 2 - Phouman Ashrafian News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia

Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Phouman ashrafianTailored covalency

BMS plans $1 5B in cuts through 25, with 2,000-plus layoffs

BMS plans $1 5B in cuts through 25, with 2,000-plus layoffs
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyDavid elkinsPhouman ashrafianAdam lenkowskySamit hirawatChris boernerBristol myers squibbChief financial officer david elkinsChief medical officerChief commercial officerBig pharmaKaruna therapeutics

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia underscore the potential of.

France generalCorentine driancourtSandrine guendoulFelix lauscherTimothy gilbertNathalie phamTarik elgoutniThomas kudsk larsenSally bainPhouman ashrafianHead of researchDrug administrationFast track designationOrphan drugVice presidentKudsk larsen

Sanofi - Aventis Groupe: Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Sanofi - Aventis Groupe: Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalFelix lauscherNathalie phamSally bainTimothy gilbertDennis riedlTarik elgoutniPhouman ashrafianSandrine guendoulCorentine driancourtThomas kudsk larsenDrug administrationHead of researchFast track designationOrphan drugVice president

Rilzabrutinib Achieves Phase 3 Primary Endpoint in Immune Thrombocytopenia

Rilzabrutinib led to a durable platelet response in adult patients with persistent or chronic immune thrombocytopenia in the LUNA 3 study.

Rilzabrutinib lunaPhouman ashrafianEuropean unionDrug administrationFast track designationOrphan drugImmune thrombocytopenicTreasure islandStatpearls publishing